Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Efavirenz to Rilpivirine for Liver Steatosis in People Living with HIV
TCTR20210403003Phase 4Not yet recruiting
- Sponsor
- Thai AIDS Society
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rilpivirine in human immunodeficiency virus infection (HIV), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Thai AIDS Society. Planned start May 2021; status: not yet recruiting.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on TCTR20210403003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210403003.